Delcath Systems, Inc. - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
DCTH Over the counter 3841 http://delcath.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Delcath Systems, Inc.

Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma - Oct 15th, 2018 6:00 am
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology - Oct 4th, 2018 6:00 am
Delcath Raises $8.1 Million from Shareholders in Rights Offering - Sep 27th, 2018 2:05 pm
Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018 - Sep 26th, 2018 6:00 am
Data on Delcath’s PHP Therapy presented at CIRSE 2018 - Sep 24th, 2018 6:00 am
Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018 - Sep 13th, 2018 6:00 am
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology - Sep 4th, 2018 6:00 am
Delcath Announces Extension of Rights Offering Period to September 26, 2018 - Aug 28th, 2018 6:33 am
Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018 - Aug 27th, 2018 7:00 am
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification - Aug 23rd, 2018 9:14 am
Delcath Announces Pending Expiration to Rights Offering Subscription Period - Aug 22nd, 2018 7:41 am
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma - Aug 21st, 2018 6:52 am
Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial - Aug 20th, 2018 6:00 am
Delcath Issues Letter to Stockholders - Aug 17th, 2018 6:00 am
Delcath Announces Second Quarter Fiscal 2018 Financial Results - Aug 15th, 2018 6:00 am
Delcath Announces Commencement of Rights Offering Subscription Period - Aug 6th, 2018 6:00 am
Summary of Calendar for Upcoming Proposed Delcath Rights Offering - Jul 31st, 2018 6:00 am
Delcath Amends Phase 3 Ocular Melanoma Trial Protocol - Jul 27th, 2018 6:00 am